Ian J. Majewski - Concepedia

Author

Ian J. Majewski

Walter and Eliza Hall Institute of Medical Research ORCID

Also Known As

I Majewski, I. J. Majewski, I. Majewski, I.J. Majewski, Ian J Majewski, Ian J. Majewski, Ian Majewski, Ian J. Majewski, Majewski, Ian, Majewski, Ian J.

134

Publications

7.1K

Citations

H-Index

Concepts

All Affiliations

Walter and Eliza Hall Institute of Medical Research The University of Melbourne Peter MacCallum Cancer Centre The Royal Melbourne Hospital The Netherlands Cancer Institute

About

Ian J. Majewski is an author at Walter and Eliza Hall Institute of Medical Research specializing in medicine, cell biology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	15	3.1K
2	Engineering	5	5	508
3	Health Sciences	2	2	295
4	Natural Sciences	2	2	1.5K
5	Biostatistics	1	1	55

Ian J. Majewski

Publications

Citations

H-Index

Page 1

	Year	Citations
The Pseudokinase MLKL Mediates Necroptosis via a Molecular Switch Mechanism James M. Murphy, Peter E. Czabotar, Joanne M. Hildebrand, Immunity Protein FunctionSignal TransductionMedicineNatural SciencesApoptosis	2013	1.2K
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML Courtney D. DiNardo, Ing Soo Tiong, Anna Quaglieri, Blood	2020	628
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia Piers Blombery, Mary Ann Anderson, Jianan Gong, Cancer Discovery	2018	412
Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial‐to‐mesenchymal transition Paul Roepman, Andreas Schlicker, Josep Tabernero, International Journal of Cancer	2013	346
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism Mary Ann Anderson, Jing Deng, John F. Seymour, Blood	2016	323
ChIP-seq analysis reveals distinct H3K27me3 profiles that correlate with transcriptional activity Matthew D. Young, Tracy A. Willson, Matthew J. Wakefield, Nucleic Acids Research Histone ModificationsEpigenetic ChangeGeneticsMolecular BiologyGene Regulatory Network	2011	305
Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations Richard W. Birkinshaw, Jianan Gong, Cindy S. Luo, Nature Communications	2019	229
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab S. Loibl, Ian J. Majewski, Valentina Guarneri, Annals of Oncology Breast OncologyMedicinePathologyPik3ca MutationsCancer Genomics	2016	225
<i>PIK3CA</i> Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2–Targeted Therapies in Breast Cancer Ian J. Majewski, Paolo Nucíforo, Lorenza Mittempergher, Journal of Clinical Oncology	2015	217
An α‐E‐catenin (<i><scp>CTNNA1</scp></i>) mutation in hereditary diffuse gastric cancer Ian J. Majewski, Irma Kluijt, Annemieke Cats, The Journal of Pathology Cancer PathologyFamily MembersGeneticsDiffuse Gastric CancersPathology	2012	216

Page 1